Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence

Breast Cancer Research and Treatment

Volumn 136, Issue 1, 2012, Pages 253-265

  Smith, Carolyn L ^a   Migliaccio, Ilenia ^a   Chaubal, Vaishali ^a   Wu, Meng Fen ^a   Pace, Margaret C ^a   Hartmaier, Ryan ^a   Jiang, Shiming ^a   Edwards, Dean P ^a   Gutiérrez, M Carolina ^a   Hilsenbeck, Susan G ^a   Oesterreich, Steffi ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Corepressor; Estrogen receptor; NCOR2; SMRT; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE MICROARRAY;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEOLUS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NUCLEAR RECEPTOR CO-REPRESSOR 2; SURVIVAL ANALYSIS; TAMOXIFEN; TISSUE ARRAY ANALYSIS;

EID: 84867864616     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2262-7     Document Type: Article

References (41)

1. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92(4):328-332
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3):321-333
3. Anderson E (2002) The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 4:197-201
4. Clarke CA, Glasser SL, Uratsu CS, Selby JV, Kushi LH, Herrington LJ (2006) Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 24:e49-e50
5. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L (2010) Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 27:4111-4119
6. Xu J, Wu RC, O'Malley BW (2009) Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 9:615-630
7. Shang Y, Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science 295(5564):2465-2468
8. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, Wong J, Allred DC, Clark GM, Schiff R (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95(5):353-361
9. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96(12):926-935
10. Smith CL, Nawaz Z, O'Malley BW (1997) Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11(6):657-666
11. Scott DJ, Parkes AT, Ponchel F, Cummings M, Poola I, Speirs V (2007) Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro. Int J Oncol 31(3):557-565
12. Sarvilinna N, Eronen H, Miettinen S, Vienonen A, Ylikomi T (2006) Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells. Int J Cancer 118(4):832-840
13. Chan CMW, Martin L-A, Johnston SRD, Ali S, Dowsett M (2002) Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. Steroid Biochem Mol Biol 81(4-5):333-341
14. Thenot S, Charpin M, Bonnet S, Cavailles V (1999) Estrogen receptor cofactors expression in breast and endometrial human cancer cells. Mol Cell Endocrinol 156(1-2):85-93
15. Magklara A, Brown TJ, Diamandis EP (2002) Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. Int J Cancer 100(5):507-514
16. Chan CMW, Lykkesfeldt AE, Parker MG, Dowsett M (1999) Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer. Clin Cancer Res 5(11):3460-3467
17. Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S, Sonoo H (2000) Expression levels of estrogen receptor-α, estrogen receptor-β, coactivators, and corepressors in breast cancer. Clin Cancer Res 6(2):512-518
18. Fleming FJ, Hill AD, McDermott EW, O'Higgins NJ, Young LS (2004) Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by β-estradiol and 4-hydroxytamoxifen in human breast cancer. J Clin Endocrinol Metab 89(1):375-383
19. van Agthoven T, Sieuwerts AM, Veldscholte J, Meijer-van Gelder ME, Smid M, Brinkman A, den Dekker AT, Leroy IM, van Ijcken WFJ, Sleijfer S, Foekens JA, Dorssers LCJ (2009) CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer. Brit J Cancer 101(11):1824-1832
20. Peterson TJ, Karmakar S, Pace MC, Gao T, Smith CL (2007) The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor-α transcriptional activity. Mol Cell Biol 27(17):5933-5948
21. Karmakar S, Gao T, Pace MC, Oesterreich S, Smith CL (2010) Cooperative activation of cyclin D1 and progesterone receptor gene expression by the SRC-3 coactivator and SMRT corepressor. Mol Endocrinol 24:1187-1202
22. Green AR, Burney C, Granger CJ, Paish EC, El-Sheikh S, Rakha EA, Powe DG, Macmillin RD, Ellis IO, Stylianou E (2008) The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. Breast Cancer Res Treat 110(3):427-437
23. Migliaccio I, Wu M-F, Gutierrez C, Malorni L, Mohsin SK, Allred DC, Hilsenbeck SG, Osborne CK, Weiss H, Lee AV (2009) Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat 123(3):651-660
24. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474-1481
25. Mohsin SK, Clark GM, Havighurst T, Weiss H, Berardo M, Roanh LD, To TV, Zhang Q, Love RR, Allred DC (2004) Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Modern Pathol 17(12):1545-1554
26. Karmakar S, Foster EA, Smith CL (2009) Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-α transcriptional activity. Endocrinology 150:1588-1596
27. Allred DC, Harvey JM, Bernardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155-168
28. Hommel G (1988) A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika 75:383-386
29. Kao J, Salari K, Bocanegra M, Choi Y-L, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD, Pollack JR (2009) Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 4(7):e6146. doi: 10.1371/journal.pone.0006146
30. Dieli-Conwright CM, Spektor TM, Rice JC, Schroeder ET (2009) Oestradiol and SERM treatments influence oestrogen receptor coregulator gene expression in human skeletal muscle cells. Acta Physiol 197(3):187-196
31. Ochsner SA, Steffen DL, Hilsenbeck SG, Chen ES, Watkins CM, McKenna NJ (2009) GEMS (Gene Expression MetaSignatures), a web resource for querying meta-analysis of expression microarray datasets: 17β-estradiol in MCF-7 cells. Canc Res 69(1):23-26
32. Stanya KJ, Liu Y, Means AR, Kao H-Y (2008) Cdk2 and Pin1 negatively regulate the transcriptional corepressor SMRT. J Cell Biol 183(1):49-61
33. Hoberg JE, Yeung F, Mayo MW (2004) SMRT derepression by the IκB kinase α: a prerequisite to NF-κB transcription and survival. Mol Cell 16(2):245-255
34. Jonas BA, Privalsky ML (2004) SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathways. J Biol Chem 279(52):54676-54686
35. Jonas BA, Varlakhanova N, Hayakawa F, Goodson M, Privalsky ML (2007) Response of SMRT (Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptor) and N-CoR (Nuclear Receptor Corepressor) corepressors to mitogen-activated protein kinase kinase kinase cascades is determined by alternative mRNA splicing. Mol Endo 21(8):1924-1939
36. Liu E, Thor A, He M, Marcos M, Ljung BM, Benz C (1992) The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 7:1027-1032
37. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56:4625-4629
38. Cheng X, Kao H-Y (2009) G protein pathway suppressor 2 (GPS2) is a transcriptional corepressor important for estrogen receptor α-mediated transcriptional regulation. J Biol Chem 284:36395-36404
39. 3 receptor signalling in prostate cancer cells. Oncogene 23:6712-6725
40. Ting H-J, Bao B-Y, Reeder JE, Messing EM, Lee Y-F (2007) Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1α, 25-dihydroxyvitamin D3 responsiveness. Mol Cancer Res 5:967-980
41. Keeton EK, Brown M (2005) Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-α and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 19(6):1543-1554